Re: Petros Grivas, Se Hoon Park, Eric Voog, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 2023;84:95-108.

Autor: Feng YN; Urology Surgery Department, Fifth Affiliated Hospital of Guangxi Medical University, Nanning, China; Urology Surgery Department, First People's Hospital of Nanning, Nanning, China. Electronic address: 317dodo@163.com., Xie GY; Urology Surgery Department, Fifth Affiliated Hospital of Guangxi Medical University, Nanning, China; Urology Surgery Department, First People's Hospital of Nanning, Nanning, China., Xiao L; Department of Critical Care Medicine, Fifth Affiliated Hospital of Guangxi Medical University, Nanning, China; Department of Critical Care Medicine, First People's Hospital of Nanning, Nanning, China.

Publikováno v: European urology [Eur Urol] 2023 Dec; Vol. 84 (6), pp. e145. Date of Electronic Publication: 2023 Aug 31.

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

Autor: Primo N. Lara, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee, Daniel Heinrich, Oleg Nikolaevich Lipatov, Craig Gedye, Erhan Gokmen, Alejandro Acevedo, Andrey Semenov, Se Hoon Park, Rustem Airatovich Gafanov, Fatih Kose, Mark Jones, Xiaoqi Du, Mihaela Munteanu, Rodolfo Perini, Toni K. Choueiri, Robert J. Motzer

Publikováno v: BMC Cancer, Vol 23, Iss S1, Pp 1-12 (2024)

Abstract Background Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined with epacadostat, an indoleamine 2,3-deoxygenase 1 selective i

Externí odkaz: https://doaj.org/article/f27c30f1bd8e406580492b76ee1bb216

Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study

Autor: Sung Hee Lim, Sung Wook Cho, Jae Hoon Chung, Wan Song, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Se Hoon Park

Publikováno v: Journal of Urologic Oncology, Vol 22, Iss 1, Pp 29-33 (2024)

Purpose To assess the feasibility and short-term efficacy of maintenance enzalutamide following first-line docetaxel plus androgen deprivation therapy (ADT) in patients with high-volume, metastatic castration-naive prostate cancer (mCNPC). Materials

Externí odkaz: https://doaj.org/article/59c2be82be10482ca9e0308e3952fac7

Re: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 2021;385:683–94

Autor: Alessandro Larcher, Francesco Montorsi, Umberto Capitanio

Publikováno v: European Urology. 81:e28

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8a5f7eed91621ea47e5766ec8ecf04db
https://doi.org/10.1016/j.eururo.2021.09.034

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

Autor: Enrique Grande, Aristotelis Bamias, Matthew D. Galsky, Eiji Kikuchi, Ian D. Davis, José Ángel Arranz, Arash Rezazadeh Kalebasty, Xavier Garcia del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Javier Puente, Jian-Ri Li, Sandrine Bernhard, Alan Nicholas, Julie Telliez, Maria De Santis

Publikováno v: European Urology Open Science, Vol 58, Iss , Pp 28-36 (2023)

Standard-of-care first-line treatment for metastatic urothelial carcinoma (mUC) is platinum-based chemotherapy (CTx). Maintenance immunotherapy is a treatment option for patients without progressive disease (PD) after induction CTx. IMvigor130 was a

Externí odkaz: https://doaj.org/article/23174f8611b2473d8705753cdcab834f